We have upgraded XVir-N-31 to express a PD-L1 blocking antibody and analyzed the impact of XVir-N-31 and XVir-N-31-anti-PD-L1 on its immunostimulatory and therapeutic effects using immunohumanized, orthotopic mouse GBM models. The gene discussed is CD274; the disease is glioblastoma.